Metagenomi Therapeutics, Inc. Deferred Revenue, Revenue Recognized
Metagenomi Therapeutics, Inc. (MGX) reported Deferred Revenue, Revenue Recognized of $300.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2026-05-11
- Metagenomi Therapeutics, Inc. deferred revenue, revenue recognized for the quarter ending 2026-03-31 was $300.00K, a 88.00% decline year-over-year.
- Metagenomi Therapeutics, Inc. deferred revenue, revenue recognized for the quarter ending 2025-09-30 was $7.90M, a 16.84% decline year-over-year.
- Metagenomi Therapeutics, Inc. deferred revenue, revenue recognized for the quarter ending 2025-06-30 was $7.50M, a 316.67% increase year-over-year.
- Metagenomi Therapeutics, Inc. deferred revenue, revenue recognized for the quarter ending 2025-03-31 was $2.50M, a 69.14% decline year-over-year.
- Metagenomi Therapeutics, Inc. deferred revenue, revenue recognized for fiscal 2024 was $21.20M, a 20.30% decline from fiscal 2023.
- Metagenomi Therapeutics, Inc. deferred revenue, revenue recognized for fiscal 2023 was $26.60M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 3 month as first filed | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 6 month as first filed | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month | Deferred Revenue, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-11 | ||||||
| 2025-09-30 | $7.90M 10-Q · filed 2025-11-12 | $17.80M 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | $7.50M 10-Q · filed 2025-08-12 | $9.90M 10-Q · filed 2025-08-12 | |||||
| 2025-03-31 | $2.50M 10-Q · filed 2026-05-11 | ||||||
| 2024-12-31 | $21.20M 10-K · filed 2026-03-05 | $26.60M 10-K · filed 2025-03-17 | |||||
| 2024-09-30 | $9.50M 10-Q · filed 2025-11-12 | $19.40M 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | $1.80M 10-Q · filed 2025-08-12 | $2.80M 10-Q · filed 2024-08-14 | $9.90M 10-Q · filed 2025-08-12 | $10.80M 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $8.10M 10-Q · filed 2025-05-13 | $52.40M 10-Q · filed 2024-05-14 | |||||
| 2023-12-31 | $26.60M 10-K · filed 2026-03-05 | $60.00M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |